7.5 C
Friday, March 31, 2023

Burning Rock (NASDAQ: BNR) Announces Partnership with IMPACT Therapeutics

Burning Rock Biotech Limited (NASDAQ: BNR) disclosed that it has inked a partnership agreement with IMPACT Therapeutics. As per the partnership, Burning Rock offers testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, which has obtained the IND clearance from the U.S. FDA for the Phase I/II clinical study and will commence soon in the U.S.

The partnership will be backed by Burning Rock’s Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) certified labs in Guangzhou, China, and California, U.S. Moreover, the two laboratories of Burning Rock, which are situated in Guangzhou, China, and California, U.S., have both got the certificate issued by the CAP and the CLIA certificate issued by the Centers for Medicare and Medicaid Services (CMS).

Furthermore, the certified laboratories have also backed the global strategic collaboration with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of synthetic lethality. It encompasses the CDx development of Senaparib.

About IMP9064

IMP9064 is an ATR inhibitor detected and created by IMPACT Therapeutics, with worldwide intellectual property rights. In preclinical studies, IMP9064 was discovered to be a highly potent ATR inhibitor and is careful against other kinases. Moreover, IMP9064 has verified high activities in several ATM-deficient cell lines and is more active than the reference compound in xenograft in vivo models. These could lead to a broader therapeutic window, improved tolerability in long-term administration as a single agent, and offer more flexibility in combination therapy.

Furthermore, Senaparib which is a PARP inhibitor developed by IMPACT Therapeutics has been discovered in several clinical studies all around the globe. IMP9064 in combination with Senaparib will be assessed in this clinical study to discover the combination therapy of an ATR inhibitor and a PARP inhibitor, which is highly expected in the DNA Damage Response (DDR) research field.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.